Archer-Daniels-Midland Co vs ADMA Biologics Inc — how do they compare? Archer-Daniels-Midland Co trades at $80.38 (market cap $38.78B), while ADMA Biologics Inc trades at $9.88 (market cap $2.22B). The key difference: Archer-Daniels-Midland Co is far larger — about 17.5× ADMA Biologics Inc's market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADM | ADMA | |
|---|---|---|
Market Cap | $38.78B | $2.22B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $20.38 |
52-Week Low | $56.00 | $7.60 |
Enterprise Value | $47.03B | $2.29B |
Dividend Yield | 2.59% | — |
Signals from Pluang's Aura AI — not financial advice
ADM trades at $80.49, up 5.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has declined from $101.6B in 2022 to $80.3B in 2025, but net income margin improved to 2.16% in 2025. The company raised its 2026 outlook after Q2 results, citing biofuels and nutrition strength. Valuation ratios include a P/E of 21.98 and P/S of 0.48, indicating potential undervaluation relative to earnings growth prospects.
Outlook is positive with analyst consensus price target of $88.00, though execution risks and competitive pressures remain. Investment opportunity lies in continued margin expansion and biofuel demand, while risks include volatile commodity prices and debt levels. The stock offers a dividend yield supported by 379 consecutive quarterly payments.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →